Systemic
fungal infections are a growing problem in contemporary
medicine and few
drugs are licensed for
therapy of
invasive fungal infections. Differences between
fungi and
humans, like the presence of a
cell wall in fungal
cells, can be explored for designing
new drugs. (1,3)-β-D-
glucan synthase, an
enzyme that catalyzes the synthesis of (1,3)-β-D-
glucan, a structural and essential component of the fungal
cell wall, is absent in
mammals and this makes it an excellent target for the development of new
antifungal agents. Papulacandins are a
family of natural
antifungal agents targeting (1,3)-β-D-
glucan synthase. In this study we describe the synthesis and
biological evaluation of two new Papulacandin analogs as potential (1,3)-β-D-
glucan synthase inhibitors.